20 articles
Researchers identify transthyretin (TTR) as a potential biomarker for postoperative cognitive dysfunction, offering new diagnostic hope.
Bilateral theta burst stimulation enhanced neural repair and restored function after stroke in non-human primates through multiple mechanisms.
A Danish double-blind RCT tests a novel at-home electromagnetic field headband against sham for moderate-to-severe depression over 8 weeks.
A UCLA mouse study identifies the specific prefrontal neuron type responsible for TMS's fast-acting antidepressant action.
New research in Cell maps the fronto-insular circuits behind accelerated TMS, potentially transforming rapid depression treatment.
Breakthrough antisense therapy demonstrates sustained benefits for rare genetic form of ALS in extended clinical trial.
A new Cell study reveals the fronto-insular circuit as the key mediator of TMS antidepressant effects, opening the door to optimized treatment.
New peptide delivery system restores brain connections and memory function in Alzheimer's models, offering hope for treating cognitive decline.
Non-invasive brain stimulation techniques like TMS are helping stroke survivors recover language abilities by targeting specific brain regions.
New review reveals promising tau-targeting therapies showing cognitive benefits and slowed brain pathology in Alzheimer's trials.
12-week mindfulness exercise program significantly improved motor tics, anxiety, and daily functioning in 121 children with Tourette syndrome.
AI-personalized neurostimulation tested in 67 UK teachers experiencing work-related rumination, with mixed but promising results.
A validated UPLC-MS/MS method analyzing 566 plasma samples reveals key patient factors that explain why standard antidepressant doses fail many people.
Comprehensive review reveals multiple supplements may enhance brain recovery after TBI through anti-inflammatory and neuroprotective mechanisms.
A Japanese RCT shows tenecteplase (0.25 mg/kg) achieves 3x higher early recanalization than low-dose alteplase (0.6 mg/kg) in LVO stroke patients.
Simple compound successfully treats life-threatening COQ2 deficiency in newborn, offering hope for rare mitochondrial disorders.
New research reveals sex differences in Alzheimer's blood biomarkers affect diagnostic accuracy and disease prediction.
A year-long sham-controlled trial finds active VNS meaningfully improves daily function and quality of life in patients who failed 4+ antidepressants.
Promising Cerebrolysin research for rare neurological disorder withdrawn, highlighting research integrity concerns.
A phase 2 RCT finds ABvac40, a vaccine targeting vascular amyloid-ฮฒ40, is safe and immunogenic in early Alzheimer's patients with no ARIA-E.
